Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II bortezomib salvage therapy study in relapsed or refractory PTCLU and CTCL
2005-005002-24Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Mar 2006
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Overall tumor response. Started Mar 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on 2005-005002-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005002-24.